Results 111 to 120 of about 6,010 (176)

Future of Pharmacometrics

Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2018
openaire   +2 more sources

Immunostimulatory and Immunodynamic Modeling Analysis to Determine a Plausible Starting Dose of mRNA-4359 for Use in First-In-Human Trials. [PDF]

CPT Pharmacometrics Syst Pharmacol
Greene SA, Channavazzala M, Paleja B, Sandhu HS, Kumar R, Attarwala H, Van L, Liang M.   +7 more
europepmc   +1 more source

Conditional Versus Unconditional Covariate Effects in Pharmacometric Models: Implications for Interpretation, Communication, and Reporting. [PDF]

CPT Pharmacometrics Syst Pharmacol
Jonsson EN, Jönsson S, Hansson E, Nyberg J.   +3 more
europepmc   +1 more source

Combining Aggregate Data and Individual Patient Data in Model-Based Meta-Analysis: An Illustrative Case Study of Tofacitinib in Rheumatoid Arthritis Patients. [PDF]

CPT Pharmacometrics Syst Pharmacol
Pham TN, Largajolli A, Sardu ML, Maringwa J, Zierhut ML, Cheung SYA.   +5 more
europepmc   +1 more source

Evaluating the Impact of Intestinal Bile Salts on Drug Absorption Using PBPK Modeling: Case Studies With Efavirenz, Cinnarizine, and Posaconazole. [PDF]

CPT Pharmacometrics Syst Pharmacol
Al-Amiry Santos LG, Polak S, Yeo KR.
europepmc   +1 more source

Pharmacometrics in children

Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2018
openaire   +2 more sources

Population Pharmacokinetics and Exposure-Response Analyses for Telisotuzumab Vedotin in Patients With c-Met Protein Overexpressing Tumors. [PDF]

CPT Pharmacometrics Syst Pharmacol
Babel H, Brunsdon P, Engelhardt B, Schmitt V, Ratajczak C, Mensing S, Menon RM, Parikh A.   +7 more
europepmc   +1 more source

Comprehensive Pathophysiology Repository for PBPK Modeling in Liver Cirrhosis: Quantifying Continuous Disease Progression and Population Variability. [PDF]

CPT Pharmacometrics Syst Pharmacol
Schneider ARP, Baier V, Schlender JF, Kuepfer L.   +3 more
europepmc   +1 more source

Population PK/PD Modeling for Evaluation of Intertwining Effects of Drug and Disease on Thrombocytopenia in Acute Leukemias. [PDF]

CPT Pharmacometrics Syst Pharmacol
Sou T, Malek K, Weber HJ.
europepmc   +1 more source

Physiologically Based Pharmacokinetic Modeling in Patients With Hepatic Impairment: Are Changes in Bosutinib Exposure Profiles Driven by Altered Absorption or Distribution? [PDF]

CPT Pharmacometrics Syst Pharmacol
Muto C, Jones HM, Yamazaki S.
europepmc   +1 more source